146 related articles for article (PubMed ID: 30557902)
41. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
Lee SJ; Campos H; Moye LA; Sacks FM
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):853-8. PubMed ID: 12637336
[TBL] [Abstract][Full Text] [Related]
42. Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases.
Yang D; Zhang J; Xu J; Zhu T; Fan Y; Fan J; Chen YE
J Vis Exp; 2013 Nov; (81):e50957. PubMed ID: 24301055
[TBL] [Abstract][Full Text] [Related]
43. Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
Hiukka A; Fruchart-Najib J; Leinonen E; Hilden H; Fruchart JC; Taskinen MR
Diabetologia; 2005 Jun; 48(6):1207-15. PubMed ID: 15864534
[TBL] [Abstract][Full Text] [Related]
44. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells.
Sol EM; Sundsten T; Bergsten P
Lipids Health Dis; 2009 Feb; 8():3. PubMed ID: 19196457
[TBL] [Abstract][Full Text] [Related]
45. Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein CIII concentrations.
Kosuge K; Miida T; Takahashi A; Obayashi K; Ito M; Ito T; Soda S; Ozaki K; Hirayama S; Hanyu O; Aizawa Y; Nakamura Y
Atherosclerosis; 2006 Feb; 184(2):413-9. PubMed ID: 16024022
[TBL] [Abstract][Full Text] [Related]
46. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII.
Wei J; Ouyang H; Wang Y; Pang D; Cong NX; Wang T; Leng B; Li D; Li X; Wu R; Ding Y; Gao F; Deng Y; Liu B; Li Z; Lai L; Feng H; Liu G; Deng X
FEBS J; 2012 Jan; 279(1):91-9. PubMed ID: 22023023
[TBL] [Abstract][Full Text] [Related]
47. Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.
Hu ZJ; Ren LP; Wang C; Liu B; Song GY
Exp Ther Med; 2014 Sep; 8(3):951-956. PubMed ID: 25120629
[TBL] [Abstract][Full Text] [Related]
48. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes.
Juntti-Berggren L; Refai E; Appelskog I; Andersson M; Imreh G; Dekki N; Uhles S; Yu L; Griffiths WJ; Zaitsev S; Leibiger I; Yang SN; Olivecrona G; Jörnvall H; Berggren PO
Proc Natl Acad Sci U S A; 2004 Jul; 101(27):10090-4. PubMed ID: 15210953
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of ApoCIII: the next PCSK9?
Bernelot Moens SJ; van Capelleveen JC; Stroes ES
Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
[TBL] [Abstract][Full Text] [Related]
50. Apolipoprotein CIII hyperactivates β cell CaV1 channels through SR-BI/β1 integrin-dependent coactivation of PKA and Src.
Shi Y; Yang G; Yu J; Yu L; Westenbroek R; Catterall WA; Juntti-Berggren L; Berggren PO; Yang SN
Cell Mol Life Sci; 2014 Apr; 71(7):1289-303. PubMed ID: 23949443
[TBL] [Abstract][Full Text] [Related]
51. Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum.
Wang Y; Song Z; Wagner JD; Pachuk C; Subramanian RR
J Lipid Res; 2011 Jun; 52(6):1265-1271. PubMed ID: 21371998
[TBL] [Abstract][Full Text] [Related]
52. CD14
Olivieri O; Gasperini S; Calzetti F; Gardiman E; Castagna A; Martinelli N; Tamassia N; Cassatella MA
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768547
[TBL] [Abstract][Full Text] [Related]
53. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.
Kawakami A; Aikawa M; Alcaide P; Luscinskas FW; Libby P; Sacks FM
Circulation; 2006 Aug; 114(7):681-7. PubMed ID: 16894036
[TBL] [Abstract][Full Text] [Related]
54. Lowering apolipoprotein CIII delays onset of type 1 diabetes.
Holmberg R; Refai E; Höög A; Crooke RM; Graham M; Olivecrona G; Berggren PO; Juntti-Berggren L
Proc Natl Acad Sci U S A; 2011 Jun; 108(26):10685-9. PubMed ID: 21670290
[TBL] [Abstract][Full Text] [Related]
55. Uncovering the role of apolipoprotein C-III in insulin resistance.
Aguilar-Recarte D; Palomer X; Vázquez-Carrera M
Clin Investig Arterioscler; 2021; 33(2):108-115. PubMed ID: 33303217
[TBL] [Abstract][Full Text] [Related]
56. Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.
Kassai A; Muniyappa R; Levenson AE; Walter MF; Abel BS; Ring M; Taylor SI; Biddinger SB; Skarulis MC; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2016 Apr; 101(4):1790-7. PubMed ID: 26900642
[TBL] [Abstract][Full Text] [Related]
57. Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families.
Bochem AE; van Capelleveen JC; Dallinga-Thie GM; Schimmel AW; Motazacker MM; Tietjen I; Singaraja RR; Hayden MR; Kastelein JJ; Stroes ES; Hovingh GK
Clin Genet; 2014 May; 85(5):433-40. PubMed ID: 23701270
[TBL] [Abstract][Full Text] [Related]
58. Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity.
Alvi SS; Ansari IA; Ahmad MK; Iqbal J; Khan MS
Biomed Pharmacother; 2017 Dec; 96():1082-1093. PubMed ID: 29174038
[TBL] [Abstract][Full Text] [Related]
59. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
[TBL] [Abstract][Full Text] [Related]
60. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.
Hiukka A; Ståhlman M; Pettersson C; Levin M; Adiels M; Teneberg S; Leinonen ES; Hultén LM; Wiklund O; Oresic M; Olofsson SO; Taskinen MR; Ekroos K; Borén J
Diabetes; 2009 Sep; 58(9):2018-26. PubMed ID: 19502413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
